Key opinion leaders in neurology discuss the safety and efficacy of apomorphine hydrochloride and provide insights into the advantages and disadvantages of its subcutaneous formulation.
Laxman Bahroo, DO
Advertisement
Associate Professor, Department of Neurology; Director, Botulinum Toxin Clinic; Director, Residency Program, Department of Neurology
Articles by Laxman Bahroo, DO
Laxman Bahroo, DO and Mindy K. Bixby, DO define OFF episodes in Parkinson’s Disease and discuss how they are often unpredictable and variable in their severity.
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
2
Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials
3
Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo
4
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
5
